Search

Objective This paper reports a case of malignant intracranial hypertension, reviews his diagnosis and treatment, and analyzes his etiology, in order to improve the clinicians' cognition of this disease. Methods and Results The patient was a 19-year-old male with subacute onset and chronic course of disease, presenting with amaurosis, headache, neck and shoulder pain, blurred vision and tinnitus disease. Imaging findings showed cerebral venous sinus stenosis (VSS) with obvious pressure difference at both ends of stenosis. However, venous sinus stenting was ineffective. After optic nerve sheath decompression, the symptoms of headache and blurred vision were not significantly improved. Finally, the patient was diagnosed as glioblastoma (WHO IV), and died 8 months after removal of the tumor foci. Conclusions Patients with the pressure difference at both ends of malignant intracranial hypertension with VSS should not take stenting. Clarifying the cause and type of stenosis is very important for correct diagnosis and guide treatment. [ABSTRACT FROM AUTHOR]

In recent years, nano-based drug delivery systems have gradually been regarded as a promising approach to improve the current glioblastoma treatment, attracting many researchers to engage in this field. To gain comprehensive insights into the advancements in the field of nano-based drug delivery systems for glioblastoma treatment over the past 24 years (1999–2022), we have undertaken a systematic scientometric analysis. This analysis aims to explore the development of the field, identify prominent research themes, and examine key trends in terms of annual publications and citations, as well as the involvement of countries, institutions, subject categories, journals, authors, and references. It was found that papers and their citations gradually grew in the past two decades. China and the United States had the most significant publications related to this field. Keywords analysis provided the research trends and hot spots or foci of this field, establishing the foundation for further discussions. The common therapies and corresponding drugs, and four main requests or tasks for nanocarriers used for drug delivery in glioma treatment were discussed. Moreover, the nine main types of nanocarriers used in this field were recognized, along with the up-to-date review of the related studies in recent three years. We hope this review will inspire novel ideas for researchers in related areas and facilitate the development of a nano-based drug delivery system for effective glioblastoma therapy. [Display omitted] • This is the first comprehensive scientometric analysis of nano-based drug delivery systems in GBM treatment. • The scientometric analysis provided a good detection of research hotspots and trends of this field. • An up-to-date review for the applications of nine types of nanocarriers in GBM treatment was made based on the bibliometric analysis. • Nanocarriers with dual targeting abilities plus combined therapies or novel therapies (e.g., immunotherapy, gene therapy) were stressed. [ABSTRACT FROM AUTHOR]

Background: Monoamine oxidase (MAO) A catalyzes oxidative deamination of monoamine neurotransmitters and dietary amines and regulates brain development and functions. Recently, we showed that MAO A mediates the progression and migration of glioma and MAO A inhibitors reduce glioma cell growth. Glioblastoma (GBM) is a common and most malignant brain tumor which is difficult to treat. Temozolomide (TMZ) is the current standard chemotherapy for glioma, but tumors usually become resistant and recur. So far, no effective therapy for TMZ-resistant glioma is available. Natural plant antimicrobial solution (PAMs) is a Chinese herbal medicine which has been used for decades without toxicity and has multiple medical functions including anti- inflammatory effects. Here, we report the effects of PAMs on glioblastoma growth. Methods: The growth of TMZ -sensitive (U251S),-resistant (U251R) human glioma cells, and mouse glioma cell line GL-26 were assessed by MTS colorimetric assay, colony formation, and cell migration assays. Male C57BL/6 mice were implanted subcutaneously or intracranial with luciferase-positive mouse glioma GL-26 cells and treated with vehicle; MAO A inhibitor clorgyline (10 mg/kg); TMZ (1 mg/kg); PAMs (48 mg/kg) alone or in combination with TMZ (1 mg/kg) for 14 days. At the end of the treatment, mice were sacrificed, MAO A catalytic activity in tumors was measured, and tumor sizes were determined by imaging and weight. Results: These results show that PAMs inhibits MAO A catalytic activity in all three glioma cell lines studied U251S, U251R, and GL-26. PAMs reduced glioma growth and has greater effects in combination with low dose of TMZ than PAMS or TMZ alone in all three cell lines as shown by MTS, colony formation, and cell migration assays. Using the subcutaneous or intracranial GL-26 glioma mouse model, PAMs reduced the tumor growth and MAO A activity, similar to the MAO A inhibitor clorgyline. Combining PAMs with non-toxic dose TMZ increased survival to a greater extent than those of PAMs or TMZ alone. Conclusions: This is the first study which suggests that PAMs alone or co-administration with low doses of TMZ may be a potential adjuvant to reduce the toxicity of TMZ and to abrogate drug resistance for the effective treatment of glioma. [ABSTRACT FROM AUTHOR]